Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.617 USD | -4.33% | -6.49% | -60.70% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-60.70% | 52.55M | - | ||
+7.52% | 111B | B+ | ||
+11.38% | 106B | B+ | ||
-12.64% | 22.24B | B+ | ||
+0.44% | 21.25B | B | ||
-4.18% | 18.97B | A- | ||
-37.85% | 18.52B | A- | ||
-8.58% | 16.81B | B | ||
+37.41% | 12.54B | C+ | ||
-23.95% | 8.09B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BLRX Stock
- BLRX Stock
- Ratings BioLineRx Ltd.